MX2011010899A - Metodo y composicion para tratar degeneracion macular. - Google Patents
Metodo y composicion para tratar degeneracion macular.Info
- Publication number
- MX2011010899A MX2011010899A MX2011010899A MX2011010899A MX2011010899A MX 2011010899 A MX2011010899 A MX 2011010899A MX 2011010899 A MX2011010899 A MX 2011010899A MX 2011010899 A MX2011010899 A MX 2011010899A MX 2011010899 A MX2011010899 A MX 2011010899A
- Authority
- MX
- Mexico
- Prior art keywords
- composition
- macular degeneration
- treating macular
- keto
- prostaglandin
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2121/00—Preparations for use in therapy
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Ophthalmology & Optometry (AREA)
- Biochemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
Se describe una composición para tratar degeneración macular en un sujeto mamífero, que comprende una cantidad efectiva de un compuesto de 15-ceto-prostaglandina, tal como éster isopropílico de 13,14- dihidro-1 5-ceto-20-etil-prostaglandina F20.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16951209P | 2009-04-15 | 2009-04-15 | |
US12/758,550 US8609729B2 (en) | 2009-04-15 | 2010-04-12 | Method for treating macular degeneration |
PCT/JP2010/057108 WO2010119986A1 (en) | 2009-04-15 | 2010-04-15 | Method and composition for treating macular degeneration |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2011010899A true MX2011010899A (es) | 2011-11-01 |
MX338490B MX338490B (es) | 2016-04-18 |
Family
ID=42981459
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2011010899A MX338490B (es) | 2009-04-15 | 2010-04-15 | Metodo y composicion para tratar degeneracion macular. |
Country Status (16)
Country | Link |
---|---|
US (2) | US8609729B2 (es) |
EP (1) | EP2419107A1 (es) |
JP (2) | JP6109476B2 (es) |
KR (1) | KR20120018158A (es) |
CN (1) | CN102458413B (es) |
AR (1) | AR076298A1 (es) |
AU (1) | AU2010237744B2 (es) |
BR (1) | BRPI1016081A2 (es) |
CA (1) | CA2757762A1 (es) |
IL (1) | IL215556A0 (es) |
MX (1) | MX338490B (es) |
NZ (1) | NZ596035A (es) |
RU (1) | RU2548762C2 (es) |
TW (1) | TWI501769B (es) |
WO (1) | WO2010119986A1 (es) |
ZA (1) | ZA201108151B (es) |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8609729B2 (en) * | 2009-04-15 | 2013-12-17 | Sucampo Ag | Method for treating macular degeneration |
CA2830896A1 (en) * | 2011-04-12 | 2012-10-18 | Yukihiko Mashima | Aqueous ophthalmic composition |
WO2014159679A1 (en) | 2013-03-12 | 2014-10-02 | The United States Of America, As Represented By The Secretary, Department Of Health & Human Services | Methods for using lubiprostone to absorb fluid from the subretinal space |
TW201545748A (zh) * | 2014-02-21 | 2015-12-16 | Univ Kagawa Nat Univ Corp | 伴隨老年性黃斑部病變的地圖狀萎縮的處置用的醫藥組成物 |
Family Cites Families (18)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1322749C (en) | 1987-01-28 | 1993-10-05 | Ryuzo Ueno | Prostaglandins of the d series, and tranquilizers and soporifics containing the same |
US5166174A (en) | 1987-01-28 | 1992-11-24 | K.K. Ueno Seiyaku Oyo Kenkyujo | Prostaglandins E and anti-ulcers containing same |
US5221763A (en) | 1987-04-30 | 1993-06-22 | R-Tech Ueno, Ltd. | Prostaglandins of the F series |
GB2209939B (en) * | 1987-09-18 | 1992-01-02 | R Tech Ueno Ltd | The use of 13,14-dihydro-15-keto-prostaglandins as ocular hypotensive agents |
US5151444B1 (en) | 1987-09-18 | 1999-07-06 | R Tech Ueno Ltd | Ocular hypotensive agents |
CA2039420C (en) | 1990-04-04 | 1996-12-10 | Ryuji Ueno | Treatment of cataract with 15-keto-prostaglandin compounds |
ES2093774T3 (es) | 1991-03-14 | 1997-01-01 | R Tech Ueno Ltd | Estimulacion de la curacion de heridas con un compuesto 15-cetoprostaglandina. |
JP2592196B2 (ja) * | 1991-10-02 | 1997-03-19 | 株式会社アールテック・ウエノ | 脈絡膜血流量増加剤 |
CA2150287C (en) | 1994-06-03 | 2004-08-10 | Ryuji Ueno | Agent for treating hepato-biliary diseases |
US6242485B1 (en) | 1996-06-10 | 2001-06-05 | R-Tech Ueno | Endothelin antagonist |
AU3588797A (en) | 1996-07-03 | 1998-01-21 | Board Of Regents Of The University Of Oklahoma, The | Enhancement of skin pigmentation by prostaglandins |
US6225348B1 (en) * | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US20040254230A1 (en) * | 2001-12-03 | 2004-12-16 | Ogidigben Miller J. | Method for treating ocular hypertension |
KR20040080439A (ko) * | 2001-12-12 | 2004-09-18 | 파마시아 코포레이션 | 에폭시-스테로이드성 알도스테론 수용체 길항제에 의한안구 질환의 치료 방법 |
US7381404B2 (en) * | 2002-07-02 | 2008-06-03 | The Regents Of The University Of California | Treatment for dry macular degeneration |
JP2009073788A (ja) * | 2007-09-21 | 2009-04-09 | Teika Seiyaku Kk | イソプロピルウノプロストン含有眼用組成物 |
US8609729B2 (en) * | 2009-04-15 | 2013-12-17 | Sucampo Ag | Method for treating macular degeneration |
WO2013074840A1 (en) * | 2011-11-15 | 2013-05-23 | Allergan, Inc. | Treatment of dry age related macular degeneration |
-
2010
- 2010-04-12 US US12/758,550 patent/US8609729B2/en not_active Expired - Fee Related
- 2010-04-14 AR ARP100101248A patent/AR076298A1/es unknown
- 2010-04-15 EP EP10718304A patent/EP2419107A1/en not_active Withdrawn
- 2010-04-15 KR KR1020117027110A patent/KR20120018158A/ko active IP Right Grant
- 2010-04-15 CA CA2757762A patent/CA2757762A1/en not_active Abandoned
- 2010-04-15 WO PCT/JP2010/057108 patent/WO2010119986A1/en active Application Filing
- 2010-04-15 TW TW099111760A patent/TWI501769B/zh not_active IP Right Cessation
- 2010-04-15 CN CN201080027395.4A patent/CN102458413B/zh not_active Expired - Fee Related
- 2010-04-15 BR BRPI1016081A patent/BRPI1016081A2/pt not_active IP Right Cessation
- 2010-04-15 MX MX2011010899A patent/MX338490B/es active IP Right Grant
- 2010-04-15 RU RU2011146128/15A patent/RU2548762C2/ru not_active IP Right Cessation
- 2010-04-15 NZ NZ596035A patent/NZ596035A/xx not_active IP Right Cessation
- 2010-04-15 AU AU2010237744A patent/AU2010237744B2/en not_active Ceased
- 2010-04-15 JP JP2011544722A patent/JP6109476B2/ja not_active Expired - Fee Related
-
2011
- 2011-10-05 IL IL215556A patent/IL215556A0/en unknown
- 2011-11-07 ZA ZA2011/08151A patent/ZA201108151B/en unknown
-
2013
- 2013-11-05 US US14/071,680 patent/US20140066506A1/en not_active Abandoned
-
2015
- 2015-07-24 JP JP2015146810A patent/JP2015205915A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CA2757762A1 (en) | 2010-10-21 |
NZ596035A (en) | 2013-06-28 |
AU2010237744B2 (en) | 2015-11-26 |
CN102458413A (zh) | 2012-05-16 |
JP2015205915A (ja) | 2015-11-19 |
US8609729B2 (en) | 2013-12-17 |
TW201039830A (en) | 2010-11-16 |
AR076298A1 (es) | 2011-06-01 |
WO2010119986A1 (en) | 2010-10-21 |
BRPI1016081A2 (pt) | 2017-07-18 |
MX338490B (es) | 2016-04-18 |
RU2548762C2 (ru) | 2015-04-20 |
RU2011146128A (ru) | 2013-05-20 |
CN102458413B (zh) | 2015-05-20 |
US20100267832A1 (en) | 2010-10-21 |
JP2012524025A (ja) | 2012-10-11 |
EP2419107A1 (en) | 2012-02-22 |
TWI501769B (zh) | 2015-10-01 |
KR20120018158A (ko) | 2012-02-29 |
ZA201108151B (en) | 2012-07-25 |
US20140066506A1 (en) | 2014-03-06 |
IL215556A0 (en) | 2011-12-29 |
JP6109476B2 (ja) | 2017-04-05 |
AU2010237744A1 (en) | 2011-11-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
IN2012DN03883A (es) | ||
BRPI1014472A8 (pt) | Método para produzir um derivado de ácido graxo, microrganismo engenheirado geneticamente, derivado de ácido graxo e composição de biocombustível | |
MX2014007255A (es) | Procesos y composiciones para incrementar la digestibilidad de los materiales celulosicos. | |
MX2019001253A (es) | Conjugados de proteina-agente activo y metodo para su preparacion. | |
MY185898A (en) | Methods for increasing tolerance to abiotic stress in plants | |
MX343362B (es) | Composicion de aceite y metodo para producir la misma. | |
MX2012005782A (es) | Procedimientos, composiciones y kits de liofilizacion. | |
MY158504A (en) | Fatty acid niacin conjugates and their uses | |
TW200714283A (en) | Method and composition for treating peripheral vascular diseases | |
MX343756B (es) | Microorganismo que produce o-fosfoserina y metodo para producir l-cisteina o derivados de la misma a partir de o-fosfoserina usando los mismos. | |
MX2012007981A (es) | Derivados de fumarato de acido graso y sus usos. | |
MX2013012165A (es) | Composicion y metodo para mejorar una respuesta inmune. | |
MX2011013466A (es) | Materiales lignocelulosicos esterificados y metodos para hacerlos. | |
NZ601029A (en) | Flavor-enriching agent | |
MX2011011229A (es) | Metodo para reducir la presion intraocular en los seres humanos. | |
WO2010030091A3 (ko) | 생물학적 헴철 생산 방법 및 그에 의해 생산된 헴철 추출물을 포함하는 철분보충 조성물 | |
MX336787B (es) | Microorganismos deseñados geneticamente que comprenden 4-hidroxibenzoil-coa tioesterasas y metodos de uso de los mismos para producir acidos grasos libes y derivados de acidos grasos. | |
MX2011010899A (es) | Metodo y composicion para tratar degeneracion macular. | |
MX2012007541A (es) | Derivados de hidroximoil-heterociclos fungicidas. | |
UA102712C2 (ru) | Композиция и способ борьбы с болезнями растений | |
WO2010127197A3 (en) | Method and composition for treating diabetic ketoacidosis | |
MX352071B (es) | Ésteres de lactato eterificados, método de producción de los mismos y uso de los mismos para intensificar el efecto de agentes protectores de plantas. | |
WO2012061086A3 (en) | Method of treating neuroendocrine tumors | |
EP2597949A4 (en) | SUBMIKROMETERZUSAMMENSETZUNGEN | |
UA103336C2 (ru) | Применение ацилциклогександионкарбоновой кислоты или ее солей в комбинации со сложными эфирами ацилциклогександионкарбоновой кислоты для улучшения роста злаковых растений |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |